替考拉宁与去甲万古霉素治疗耐甲氧西林金黄色葡萄球菌肺部感染患者的临床研究

发布时间：2018-05-07 20:35

本文选题：重症监护病房 + 耐甲氧西林金黄色葡萄球菌　；参考：《中华医院感染学杂志》2015年14期

【摘要】：目的探讨替考拉宁与去甲万古霉素治疗ICU耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染患者的疗效,为治疗MRSA肺部感染提供参考依据。方法选取2007年11月-2013年9月ICU收治的73例MRSA肺部感染患者,将其分为两组,治疗组37例患者给予替考拉宁治疗,对照组36例患者给予去甲万古霉素治疗,分析比较两组患者治疗后的疗效,采用SPSS 12.0软件进行统计分析。结果治疗组总有效率为89.19%、病原菌清除率为91.89%、不良反应发生率为21.62%,对照组总有效率为69.44%、病原菌清除率为72.22%、不良反应发生率为50.00%,治疗组总有效率、病原菌清除率较高,不良反应发生率较低,两组差异有统计学意义(P0.05)。结论替考拉宁与去甲万古霉素均可有效治疗ICU患者MRSA肺部感染,但替考拉宁的疗效更佳,清除率较高,不良反应少。
[Abstract]:Objective to investigate the efficacy of teicoplanin and norvancomycin in the treatment of ICU pulmonary infection with methicillin-resistant staphylococcus aureus. Methods from November 2007 to September 2013, 73 patients with ICU pulmonary infection were divided into two groups: the treatment group (37 cases) was treated with teicoplanin, the control group (36 cases) was treated with norvancomycin. The curative effect of the two groups after treatment was analyzed and analyzed by SPSS 12.0 software. Results in the treatment group, the total effective rate was 89.19, the pathogen clearance rate was 91.89, the incidence of adverse reactions was 21.622am, the total effective rate of the control group was 69.44, the pathogen clearance rate was 72.22, and the adverse reaction rate was 50.00.The total effective rate and the pathogen clearance rate in the treatment group were higher than those in the control group. The incidence of adverse reactions was lower and the difference between the two groups was statistically significant (P 0.05). Conclusion both teicoplanin and norvancomycin are effective in the treatment of MRSA pulmonary infection in patients with ICU, but teicoplanin has better efficacy, higher clearance rate and less adverse reactions.
【作者单位】：河北联合大学附属医院重症医学科;
【基金】：国家自然科学青年基金资助项目(30900494)
【分类号】：R563.1

【参考文献】